Re-evaluating Subsequent Treatment Options in Non-small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors

Clin Oncol (R Coll Radiol). 2022 Jul;34(7):469-471. doi: 10.1016/j.clon.2022.04.006. Epub 2022 Apr 23.

Author

Affiliation

¹ Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK; Northern Centre for Cancer Care, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: [email protected].

PMID: 35474003
DOI: 10.1016/j.clon.2022.04.006

No abstract available

Publication types

Editorial
Comment

MeSH terms

CTLA-4 Antigen
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Lung Neoplasms* / drug therapy
Programmed Cell Death 1 Receptor

Substances

CTLA-4 Antigen
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor